|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
capsule
|
|
gptkbp:approvalYear
|
2018-10-16
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
L01XX62
|
|
gptkbp:brand
|
gptkb:Talzenna
|
|
gptkbp:CASNumber
|
1207456-01-6
|
|
gptkbp:chemicalFormula
|
C19H14F2N6O
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
gptkb:talazoparib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Talzenna
|
|
gptkbp:indication
|
gptkb:cancer
HER2-negative breast cancer
germline BRCA-mutated breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PARP inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A
|
|
gptkbp:molecularWeight
|
380.35 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prescribes
|
adults
metastatic breast cancer
locally advanced breast cancer
|
|
gptkbp:prescriptionRequired
|
https://labeling.pfizer.com/ShowLabeling.aspx?id=11136
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
neutropenia
thrombocytopenia
|
|
gptkbp:bfsParent
|
gptkb:talazoparib
|
|
gptkbp:bfsLayer
|
6
|